134 related articles for article (PubMed ID: 35216677)
1. Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?
Teillaud JL; Dieu-Nosjean MC
Cancer Cell; 2022 Mar; 40(3):240-243. PubMed ID: 35216677
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
Patil NS; Nabet BY; Müller S; Koeppen H; Zou W; Giltnane J; Au-Yeung A; Srivats S; Cheng JH; Takahashi C; de Almeida PE; Chitre AS; Grogan JL; Rangell L; Jayakar S; Peterson M; Hsia AW; O'Gorman WE; Ballinger M; Banchereau R; Shames DS
Cancer Cell; 2022 Mar; 40(3):289-300.e4. PubMed ID: 35216676
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
4. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
6. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
7. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
8. PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
Di Federico A; De Giglio A; Nuvola G; Deiana C; Conci N; Gelsomino F; Ardizzoni A
Future Oncol; 2021 Nov; 17(32):4415-4424. PubMed ID: 34402681
[No Abstract] [Full Text] [Related]
9. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
10. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
[TBL] [Abstract][Full Text] [Related]
12. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L; Brunet M; Guégan JP; Rey C; Bougouin A; Cousin S; Moulec SL; Besse B; Loriot Y; Larroquette M; Soubeyran I; Toulmonde M; Roubaud G; Pernot S; Cabart M; Chomy F; Lefevre C; Bourcier K; Kind M; Giglioli I; Sautès-Fridman C; Velasco V; Courgeon F; Oflazoglu E; Savina A; Marabelle A; Soria JC; Bellera C; Sofeu C; Bessede A; Fridman WH; Loarer FL; Italiano A
Nat Cancer; 2021 Aug; 2(8):794-802. PubMed ID: 35118423
[TBL] [Abstract][Full Text] [Related]
13. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
[TBL] [Abstract][Full Text] [Related]
14. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
Front Immunol; 2021; 12():665133. PubMed ID: 33936103
[TBL] [Abstract][Full Text] [Related]
15. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S; Truntzer C; Perrichet A; Limagne E; Fumet JD; Richard C; Elkrief A; Routy B; Rébé C; Ghiringhelli F
Oncoimmunology; 2020 Oct; 9(1):1836766. PubMed ID: 33178495
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
Rosner S; Forde PM
J Thorac Oncol; 2022 Apr; 17(4):503-509. PubMed ID: 35307107
[No Abstract] [Full Text] [Related]
18. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
19. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
Hendriks LEL; Remon J; Reck M
J Thorac Oncol; 2022 Apr; 17(4):499-502. PubMed ID: 35307106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
